Share
The show that helps you maximize your wealth by turning complex financial situations into actionable advice. On Your Money. Your Mission., we answer the questions you’ve been asking about -- financial planning, investing, retirement and everything in between. Whether you’re navigating the complexities of the market or looking for the best ways to save or spend your money, tune in to hear from experienced financial advisors with JFG. Walk away from each episode with savvy tips and financial t ...
…
continue reading
Manage episode 523269933 series 3393722
Content provided by Bloomberg. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Bloomberg or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Compass Pathways is a mental health care company developing new treatments for people who haven’t responded to existing medications and continue to struggle with their mental health. The company was the first to report successful Phase 3 clinical trial results for a psychedelic treatment, known as COMP360 psilocybin, for treatment-resistant depression (TRD) and is positioned to potentially be the first to receive regulatory approval and bring a psychedelic-based medicine to market.
Kabir Nath, the CEO of Compass Pathways, details his company's path building a scalable, safe, and accessible psychedelic care system and model. Kabir speaks with Carol Massar and Alexis Christoforous on Bloomberg Businessweek Daily.
See omnystudio.com/listener for privacy information.
5062 episodes
))
